MMP-9 Inhibitors for Neurodegeneration

MMP-9 Inhibitors for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">MMP-9 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">SB-3CT</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Prinomastat (AG-3340)</td>
<td>Discontinued (cancer)</td>
</tr>
<tr>
<td class="label">ANDRO</td>
<td>Research compound</td>
</tr>
<tr>
<td class="label">MMPI-based designs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MMP-9 (Matrix Metalloproteinase-9, Gelatinase B)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Matrix metalloproteinase inhibitor</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Zinc-chelating or substrate mimic</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Broader MMPs vs. selective</td>
</tr>
</table>

Matrix Metalloproteinase-9 (MMP-9, also known as gelatinase B) is a zinc-dependent endopeptidase that degrades components of the extracellular matrix and plays important roles in tissue remodeling, synaptic plasticity, and blood-brain barrier (BBB) function. Dysregulated MMP-9 activity contributes to neurodegeneration through BBB disruption, inflammatory cell migration, and abnormal protein processing. MMP-9 inhibitors represent a therapeutic approach to restore vascular and neuronal homeostasis. [@vp2019]

MMP-9 Biology

MMP-9 Inhibitors for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">MMP-9 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">SB-3CT</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Prinomastat (AG-3340)</td>
<td>Discontinued (cancer)</td>
</tr>
<tr>
<td class="label">ANDRO</td>
<td>Research compound</td>
</tr>
<tr>
<td class="label">MMPI-based designs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MMP-9 (Matrix Metalloproteinase-9, Gelatinase B)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Matrix metalloproteinase inhibitor</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Zinc-chelating or substrate mimic</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Broader MMPs vs. selective</td>
</tr>
</table>

Matrix Metalloproteinase-9 (MMP-9, also known as gelatinase B) is a zinc-dependent endopeptidase that degrades components of the extracellular matrix and plays important roles in tissue remodeling, synaptic plasticity, and blood-brain barrier (BBB) function. Dysregulated MMP-9 activity contributes to neurodegeneration through BBB disruption, inflammatory cell migration, and abnormal protein processing. MMP-9 inhibitors represent a therapeutic approach to restore vascular and neuronal homeostasis. [@vp2019]

MMP-9 Biology

MMP-9 is encoded by the [MMP9](/genes/mmp9) gene. Key features include:

• Enzyme: Zinc-dependent endopeptidase
• Substrates: Collagen IV, gelatin, elastin, laminin, TNF-α, IL-1β
• Expression: Neutrophils, macrophages, microglia, neurons, endothelial cells
• Regulation: Tightly controlled by TIMP-1 (tissue inhibitor of metalloproteinases-1)

Mechanism of Action

MMP-9 inhibitors work through enzyme inhibition and BBB protection:

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

MMP-9 inhibitors may benefit AD through:

• Preservation of BBB integrity
• Reduced neuroinflammation
• Protection of neuronal connectivity
• Potential effects on amyloid processing

Parkinson's Disease

MMP-9 inhibitors are relevant for PD:

• BBB disruption in substantia nigra
• Protection of dopaminergic neurons
• Reduced neuroinflammation
• Potential for disease modification

Other Applications

• Stroke
• Traumatic Brain Injury
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Vascular Dementia](/diseases/vascular-dementia)

Drug Development

MMP-9 inhibitors are in various stages:

Drug Properties

Side Effects

• Musculoskeletal effects (class effect of MMPIs)
• Tendonitis
• Gastrointestinal effects
• Potential for impaired wound healing

References

Related Pages

• [BBB Protection](/therapeutics/blood-brain-barrier-therapeutic-strategies-cbs-psp)
• [Extracellular Matrix](/therapeutics/extracellular-matrix-integrin-modulator-therapy-neurodegeneration)
• [Neuroinflammation](/therapeutics/neuroinflammation-modulation-therapies)
• [MMP9 Gene](/genes/mmp9)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;